WW stock forecast, quote, news & analysis

Key Takeaways

• WW International shares have fallen approximately 14% over the last 30 days, dropping from $15.99 on June 26 to $13.71 as of July 28, 2026.
• The decline represents a sharp reversal after the stock rallied nearly 100% from late-April lows near $9 to mid-June highs above $19.50.
• Profit-taking, declining trading volumes, and waning momentum following the May-June surge appear to be primary drivers of the recent pullback.
• Over the broader quarter, the stock remains up approximately 35% from late April, reflecting strong clinical subscriber growth and strategic partnership announcements.
• Investors are closely watching the upcoming Q2 2026 earnings report on August 5 for fresh insight into member trends and the company's GLP-1 strategy.

WW International (WW) Company Overview and Market Position

WW International, known as Weight Watchers, is a global leader in science-backed weight management with over 60 years of brand heritage. The company offers a tiered membership platform spanning behavioral-only programs (Core and Core+) and clinical weight-loss solutions (Med+) that integrate GLP-1 medication access with coaching, community support, and nutritional guidance. Following its emergence from Chapter 11 restructuring, WW has repositioned itself as a comprehensive weight-health ecosystem designed for the GLP-1 era. Investors track the stock closely due to the company's pivot into prescription weight-loss medications, its partnerships with retailers and telehealth providers, and its ability to convert legacy behavioral members into higher-ARPU clinical subscribers.

WW International (WW) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, WW shares have declined roughly 14%, falling from a June 26 close of $15.99 to $13.71 as of July 28. The stock drifted steadily lower through July, losing the $15 support level mid-month and briefly touching $12.78 intraday on July 24 before staging a modest rebound. Daily trading volumes contracted meaningfully during this period, with several sessions recording fewer than 30,000 shares traded, compared with averages exceeding 200,000 during the May rally.

The last quarter presents a dramatically different picture. From its late-April trough around $9.12 on April 21, WW shares more than doubled, peaking at $19.58 on June 11. This surge was fueled by the company's Q1 2026 earnings release in early May, which highlighted 51% sequential clinical subscriber growth, several high-profile insider stock purchases, and the announcement of a partnership with Sam's Club. Despite the recent 30-day pullback, the stock remains approximately 35% higher than its levels in late April, reflecting the quarter's net positive momentum.

What Drove WW Stock Price in the Last 30 Days

The 14% decline over the past 30 days appears driven by several converging factors rather than a single catalyst. Most notably, the stock entered a pronounced cooling-off period after its dramatic late-spring rally, as momentum traders and short-term speculators took profits following the nearly 100% surge from April lows. Trading volume in July dropped sharply, suggesting reduced institutional and retail conviction at higher price levels.

Additionally, analysts at Simply Wall St reported on July 10 that consensus fair value estimates for WW were reduced by approximately 42%, from $60 to $35, citing a higher discount rate, slightly weaker long-term revenue assumptions, and a materially lower forward P/E multiple. While the revised estimate still implies significant upside from current levels, the downward revision likely pressured sentiment. Broader macro headwinds for small-cap and consumer-discretionary names may have compounded the selling. The company also scheduled its Q2 2026 earnings call for August 5, and pre-earnings uncertainty often subdues speculative positioning in volatile names like WW.

What Drove WW Stock Performance Over the Last Quarter

WW's quarterly performance has been defined by high volatility and a powerful, if uneven, recovery narrative. The stock bottomed in late April near $9 after a prolonged post-restructuring selloff, then surged through May and early June on a wave of positive developments. The Q1 2026 earnings report released May 7 confirmed that clinical subscription revenue grew 32% year-over-year and end-of-period clinical subscribers jumped 46%, while the Core+ tier returned to growth for the first time in years. Management reaffirmed full-year revenue guidance of $620 million to $635 million and adjusted EBITDA of $105 million to $115 million.

Insider buying provided an additional confidence signal during May, with multiple directors and executives purchasing shares. The Sam's Club partnership, which offers Plus members a complimentary three-month Weight Watchers Core membership, expanded WW's distribution reach significantly. The company was also added to several Russell indices, including the Russell 3000E and Russell Microcap Index. Activist investor Galloway Capital Partners publicly urged the board to take steps to unlock shareholder value, including hiring a CEO with consumer health and digital wellness expertise. These events collectively fueled the quarter's dramatic upside, even as the stock has since retraced a portion of those gains.

Trending AI Robots

For investors seeking data-driven approaches to navigate volatile stocks like WW, Tickeron's Trending AI Robots page offers a curated selection of top-performing algorithmic trading bots. Tickeron supports hundreds of AI-powered trading bots that analyze thousands of tickers, but the Trending AI Robots section highlights only those bots demonstrating the strongest recent performance and relevance to current market conditions. Each bot employs distinct strategies across various timeframes, allowing traders to explore approaches ranging from short-term momentum to longer-term trend following based on transparent, quantitative metrics. Exploring this section can help traders identify AI-driven tools aligned with their own market perspective.

WW Stock Forecast Drivers: What Investors Should Watch Next

The most immediate catalyst for WW shares is the Q2 2026 earnings report scheduled for August 5, 2026. Investors will scrutinize clinical subscriber net additions, the trajectory of the Core+ tier, ARPU trends, and any updates to full-year guidance. The Medicare GLP-1 Bridge Program, which launched July 1 and offers eligible Part D members GLP-1 medications at $50 per month alongside WW's clinical and behavioral support, represents a potentially significant growth avenue. The expansion of oral GLP-1 medications continues to broaden the addressable market for Med+. Competitive dynamics in the weight-loss industry, ongoing debt management — including the $37 million term loan prepayment executed in Q2 — and the search for a permanent CEO remain key variables. Broader macroeconomic conditions affecting consumer discretionary spending and small-cap risk appetite will also influence the stock's trajectory.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations